First Patient Enrolled in Extension Trial for Tirasemtiv to Treat ALS
Cytokinetics has enrolled the first patient in the VIGOR-ALS extension trial (NCT02936635), which will assess the effects of…
Articles by Margarida Azevedo, MSc
Les Turner ALS Walk for Life on Track to Raise $1M for Research, Patient Services, Education
The Les Turner ALS Foundation had about 7,000 people on more than 200 teams support those affected by amyotrophic lateral sclerosis…
FDA Names Ibudilast an Orphan Drug as Possible ALS Treatment
The U.S. Food and Drug Administration (FDA) has designated  MediciNova’s Ibudilast (MN-166) an orphan drug as a potential treatment for amyotrophic lateral sclerosis…
11th Anniversary of ‘Tradition of Hope’ Gala Raises Funds for ALS
Augie’s Quest announced the 11th annual ‘Tradition of Hope’ gala event will be held Oct. 15 at the Beverly…
New Preclinical Data of Masitinib for ALS Presented at 4 Scientific Meetings This Year
AB Science has been invited to present new preclinical studies on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) at…
Irish Researchers Will Visit Latin America to Gather Data About Mixed Ancestry and ALS
Researchers at Trinity College Dublin will head to Latin America to investigate whether the probability of developing amyotrophic lateral sclerosis…
Masitinib Marketing Application for ALS Accepted by European Medicines Agency
AB Science recently announced that the European Medicines Agency (EMA) has accepted a conditional marketing authorization application for the tyrosine kinase inhibitor …
Second Phase 2 Trial of NP001 for ALS Therapy is Underway
Neuraltus Pharmaceuticals has initiated the second Phase 2 clinical trial of NP001 for the treatment of amyotrophic lateral…
Smoking Speeds Progression of ALS and Reduces Survival Longevity
Cigarette smoking may speed progression of amyotrophic lateral sclerosis (ALS) and reduce survival in patients with the disease, according to a…
Phase 2 Study of Treatment for ALS-Induced Cramps, FLX-787, Underway in Australia
Flex Pharma has begun a Phase 2 clinical trial assessing FLX-787 in patients with amyotrophic lateral sclerosis (ALS).